Vnitr Lek 2018, 64(12):1148-1152

Bilirubin: from an unimportant waste product to important myocardial infarction predictor

Jaroslav A. Hubáček1,*, Libor Vítek2,3
1 Centrum experimentální medicíny IKEM, Praha
2 IV. interní klinika 1. LF UK a VFN v Praze
3 Ústav lékařské biochemie a laboratorní diagnostiky 1. LF UK a VFN v Praze

Bilirubin is the major catabolic product of heme degradation. It has long been regarded as an unimportant waste product. However, within the last twenty-five years, it has been demonstrated to play a very important role in maintaining the body's redox equilibrium. Disturbances of this equilibrium - increased oxidative stress - are currently considered one of the major risk factors for the development of non-communicable diseases. Although the exact mechanism is not known, a number of human studies have proved a reduced incidence of a number of (especially cardiovascular but also cancer) diseases in individuals with mildly elevated bilirubin concentrations.

Keywords: bilirubin; cardiovascular disease; morbidity; mortality

Received: October 22, 2018; Accepted: November 15, 2018; Published: December 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hubáček JA, Vítek L. Bilirubin: from an unimportant waste product to important myocardial infarction predictor. Vnitr Lek. 2018;64(12):1148-1152.
Download citation

References

  1. Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med 2013; 369(14): 1336-1343. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra1109345>. Go to original source... Go to PubMed...
  2. Wu LL. Review of risk factors for cardiovascular diseases. Ann Clin Lab Sci 1999; 29(2): 127-133.
  3. Hubacek JA, Stanek V, Gebauerova M et al. Traditional risk factors of acute coronary syndrome in four different male populations - total cholesterol value does not seem to be relevant risk factor. Physiol Res 2017; 66(Suppl 1): S121-S128. Go to original source... Go to PubMed...
  4. Tamosiunas A, Luksiene D, Baceviciene M et al. Health factors and risk of all-cause, cardiovascular, and coronary heart disease mortality: findings from the MONICA and HAPIEE studies in Lithuania. PLoS One 2014; 9(12): e114283. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0114283>. Go to original source... Go to PubMed...
  5. Petursson H, Sigurdsson JA, Bengtsson C et al. Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study. J Eval Clin Pract 2012; 18(1): 159-168. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2753.2011.01767.x>. Go to original source... Go to PubMed...
  6. Hubáček J. Základy genetické determinace civilizačních onemocnění. Postgrad Med 2018; 20(Supl 1): 6-10.
  7. O'Donnell CJ, Nabel EG. Genomics of cardiovascular disease. N Engl J Med 2011; 365(22): 2098-2109. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra1105239>. Go to original source... Go to PubMed...
  8. Ezzati M, Riboli E. Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med 2013; 369(10): 954-964. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra1203528>. Go to original source... Go to PubMed...
  9. Koene RJ, Prizment AE, Blaes A et al. Shared risk factors in cardiovascular disease and cancer. Circulation 2016; 133(11): 1104-1114. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.115.020406>. Go to original source... Go to PubMed...
  10. Virchow R. Die Pathologischen Pigmente. In Virchow R, Reinhardt B (eds). Archiv für pathologische Anatomie und Physiologie und Klinische Medicin (Virchow's Archiv) 1847; 1:407. Dostupné z DOI: <http://doi.org/10.1007/BF02114470>.
  11. Vitek L, Ostrow JD. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr Pharm Des 2009; 15(25): 2869-2883. Go to original source... Go to PubMed...
  12. Zucker SD, Horn PS, Sherman KE. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology 2004; 40(4): 827-835. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.20407>. Go to original source... Go to PubMed...
  13. Johnson AD, Kavousi M, Smith AV et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 2009; 18(14): 2700-2710. Dostupné z DOI: <http://dx.doi.org/10.1093/hmg/ddp202>. Go to original source... Go to PubMed...
  14. Stocker R, Yamamoto Y, McDonagh AF et al. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235(4792): 1043-1046. Go to original source... Go to PubMed...
  15. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 2006; 86(2): 583-650. Dostupné z DOI: <http://dx.doi.org/10.1152/physrev.00011.2005>. Go to original source... Go to PubMed...
  16. Vítek L. Úloha bilirubínu v prevenci kardiovaskulárních a nádorových onemocnění. Čas Lék Česk 2016; 155(2): 10-14. Go to PubMed...
  17. Vítek L. Bilirubin and atherosclerotic diseases. Physiol Res 2017; 66(Suppl 1): S11-S20. Go to original source... Go to PubMed...
  18. Vítek L. Vztah bilirubinu k nemocem vyvolaným zvýšeným oxidačním stresem. Vnitř Lék 2013; 59(7): 618-621. Go to PubMed...
  19. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994; 40(1): 18-23. Go to original source...
  20. Hopkins PN, Wu LL, Hunt SC et al. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1996; 16(2): 250-255. Go to original source... Go to PubMed...
  21. Kunutsor SK, Bakker SJ, Gansevoort RT et al. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol 2015; 35(3): 716-724. Dostupné z DOI: <http://dx.doi.org/10.1161/ATVBAHA.114.304929>. Go to original source... Go to PubMed...
  22. Kang SJ, Kim D, Park HE et al. Elevated serum bilirubin levels are inversely associated with coronary artery atherosclerosis. Atherosclerosis 2013; 230(2): 242-248. <http://dx.doi.org/10.1016/j.atherosclerosis.2013.06.021>. Go to original source... Go to PubMed...
  23. Horsfall LJ, Nazareth I, Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation 2012; 126(22): 2556-2564. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.112.114066>. Go to original source... Go to PubMed...
  24. Marconi VC, Duncan MS, So-Armah K et al. Bilirubin is inversely associated with cardiovascular disease among HIV-positive and HIV-negative individuals in VACS (Veterans Aging Cohort Study). J Am Heart Assoc 2018; 7(10): pii: e007792. Dostupné z DOI: <http://dx.doi.org/10.1161/JAHA.117.007792>. Go to original source... Go to PubMed...
  25. Suh S, Cho YR, Park MK et al. Relationship between serum bilirubin levels and cardiovascular disease. PLoS One 2018; 13(2): e0193041. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0193041>. Go to original source... Go to PubMed...
  26. Lingenhel A, Kollerits B, Schwaiger JP et al. Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease. Exp Gerontol 2008; 43(12): 1102-1107. Dostupné z DOI: <http://dx.doi.org/10.1016/j.exger.2008.08.047>. Go to original source... Go to PubMed...
  27. Breimer LH, Mikhailidis DP. Is bilirubin a marker of vascular disease and/or cancer and is it a potential therapeutic target? Curr Pharm Des 2011; 17(33): 3644-3655. Go to original source... Go to PubMed...
  28. Wagner KH, Wallner M, Mölzer C et al. Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. Clin Sci (Lond) 2015; 129(1): 1-25. <http://dx.doi.org/10.1042/CS20140566>. Go to original source... Go to PubMed...
  29. Gazzin S, Vitek L, Watchko J et al. A novel perspective on the biology of bilirubin in health and disease. Trends Mol Med 2016; 22: 758-768. Go to original source... Go to PubMed...
  30. Oda E. Does serum builirubin prevent cardiovascular disease? J Xiangya Med 2017; 2: 58. Dostupné z DOI: <http://dx.doi.org/10.21037/jxym.2017.07.05>. Go to original source...
  31. Ong KL, Allison MA, Cheung BM et al. The relationship between total bilirubin levels and total mortality in older adults: the United States National Health and Nutrition Examination Survey (NHANES) 1999-2004. PLoS One 2014; 9(4): e94479. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0094479>. Go to original source... Go to PubMed...
  32. Mahabadi AA, Lehmann N, Möhlenkamp S et al. Association of bilirubin with coronary artery calcification and cardiovascular events in the general population without known liver disease: the Heinz Nixdorf Recall study. Clin Res Cardiol 2014; 103(8): 647-653. Dostupné z DOI: <http://dx.doi.org/10.1007/s00392-014-0697-z>. Go to original source... Go to PubMed...
  33. Kimm H, Yun JE, Jo J et al. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 2009; 40(11): 3422-3427. Dostupné z DOI: <http://dx.doi.org/10.1161/STROKEAHA.109.560649>. Go to original source... Go to PubMed...
  34. Gul M, Kalkan AK, Uyarel H. Serum bilirubin: a friendly or an enemy against cardiovascular diseases? J Crit Care 2014; 29(2): 305-306. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcrc.2013.11.019>. Go to original source... Go to PubMed...
  35. Stender S, Frikke-Schmidt R, Nordestgaard BG et al. Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis. J Intern Med 2013; 273(1): 59-68. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2796.2012.02576.x>. Go to original source... Go to PubMed...
  36. Bian LQ, Li RZ, Zhang ZY et al. Effects of total bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease. J Bone Miner Metab 2013; 31(6): 637-643. Dostupné z DOI: <http://dx.doi.org/10.1007/s00774-013-0452-y>. Go to original source... Go to PubMed...
  37. Apperley S, Park HY, Holmes DT et al. Serum bilirubin and disease progression in mild COPD. Chest 2015; 148(1): 169-175. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.14-2150>. Go to original source... Go to PubMed...
  38. Peng F, Deng X, Yu Y et al. Serum bilirubin concentrations and multiple sclerosis. J Clin Neurosci 2011; 18(10): 1355-1359. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jocn.2011.02.023>. Go to original source... Go to PubMed...
  39. Balta S, Balta I, Mikhailidis DP et al. Bilirubin levels and their association with carotid intima media thickness and high-sensitivity C-reactive protein in patients with psoriasis vulgaris. Am J Clin Dermatol 2014; 15(2): 137-142. Dostupné z DOI: <http://dx.doi.org/10.1007/s40257-014-0069-5>. Go to original source... Go to PubMed...
  40. Zhao J, Tan S, Liu F et al. Heme oxygenase and ocular disease: a review of the literature. Curr Eye Res 2012; 37(11): 955-960. Dostupné z DOI: <http://dx.doi.org/10.3109/02713683.2012.700753>. Go to original source... Go to PubMed...
  41. Vitek L, Novotná M, Lenícek M et al. Serum bilirubin levels and UGT1A1 promoter variants in patients with schizophrenia. Psychiatry Res 2010; 178(2): 449-450. Dostupné z DOI: <http://dx.doi.org/10.1016/j.psychres.2009.12.008>. Go to original source... Go to PubMed...
  42. Gama-Marques J, Tinoco I, Pedro I et al. Unconjugated bilirubin and acute schizophrenia: a probable correlation? Actas Esp Psiquiatr 2017; 45(2): 79-88.
  43. Cao L, Xue L, Luo DM. Lower serum bilirubin concentration in patients with migraine. Int J Clin Exp Med 2015; 8(8): 13398-13402.
  44. Kim TS, Pae CU, Yoon SJ et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21(4): 344-348. Dostupné z DOI: <http://dx.doi.org/10.1002/gps.1469>. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.